DrugPatentWatch Database Preview
Pharmacyclics Inc Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?
PHARMACYCLICS INC has two approved drugs.
There are thirty-four US patents protecting PHARMACYCLICS INC drugs.
There are two hundred and forty-seven patent family members on PHARMACYCLICS INC drugs in thirty-nine countries and twenty-seven supplementary protection certificates in eleven countries.
Summary for Pharmacyclics Inc
| International Patents: | 247 |
| US Patents: | 34 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Pharmacyclics Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | 8,497,277 | Start Trial | Start Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | 9,125,889 | Start Trial | Start Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for PHARMACYCLICS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 280 mg and 420 mg | ➤ Subscribe | 2018-12-14 |
| ➤ Subscribe | Tablets | 140 mg and 560 mg | ➤ Subscribe | 2018-11-05 |
| ➤ Subscribe | Capsules | 70 mg | ➤ Subscribe | 2018-12-14 |
International Patents for Pharmacyclics Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2532234 | Start Trial |
| Japan | 6236071 | Start Trial |
| Israel | 239155 | Start Trial |
| Japan | 2018012710 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharmacyclics Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2201840 | 15C0029 | France | Start Trial | PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023 |
| 2201840 | 233 5006-2015 | Slovakia | Start Trial | PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023 |
| 2201840 | 122015000027 | Germany | Start Trial | PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
| 2201840 | C300728 | Netherlands | Start Trial | PRODUCT NAME: IBRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
